TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06077500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study: NCT06244810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual retainer from Fiber
Description: lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual retainer from metal
Description: lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional retianer from braided
Description: lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
Study: NCT05934994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
Study: NCT06271616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT05525858

Intervention type: DRUG
Intervention: Erlotinib
Description: EGFR Exon 19 deletions in the region E746_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I

Intervention type: DRUG
Intervention: Trastuzumab + Pertuzumab
Description: ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board

Intervention type: DRUG
Intervention: Trastuzumab emtansine
Description: ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 \> AVCV, G776_V777 \> AVGCV, G776_V777 \> VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board

Intervention type: DRUG
Intervention: Vemurafenib
Description: BRAF_V600E/D/K/R mutations

Intervention type: DRUG
Intervention: Bevacizumab + Erlotinib
Description: FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board

Intervention type: DRUG
Intervention: Entrectinib
Description: ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board

Intervention type: DRUG
Intervention: Pralsetinib
Description: RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
Study: NCT05436327

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Geriatric Assessment
Description: Clinical staff receive (a) training in GA and workflow management strategies (\<60 minutes) at baseline, (b) monthly facilitation and technical support calls (15-30 minutes) for 12 months, and (c) a group-based quarterly call for 12 months. For 12 months, clinical staff implement GA strategies during visits with older adult (65+) patients planning to receive new chemotherapy regimen and their care partners/caregivers.
Study: NCT05475366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
Description: Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers of tumor signatures (translational studies)
Description: Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
Study: NCT05031416

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LTQ
Description: The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
Study: NCT06070870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening
Study: NCT06271616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT05011058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat in combination with valganciclovir
Description: Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles
Study: NCT04670068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.B7-H3
Description: Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 IV for 3 consecutive days
Study: NCT06064864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab-Dyyb
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab-Dyyb
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab-Dyyb
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
Study: NCT05319249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK cells will be given as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib 1 MG [Talzenna]
Description: Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
Study: NCT05563428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: A free gingival graft will be carried out for recession treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: The pouch technique with a connective tissue graft will be carried out for recession treatment.
Study: NCT05375994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and adagrasib
Description: The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and adagrasib
Description: The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
Study: NCT06369415

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour
Study: NCT06069583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support platform
Description: The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support platform
Description: The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D.
Study: NCT04583579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMV inserter (DMV® MagicTouch™) with an open end
Description: This is a device used to help apply scleral lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMV inserter (DMV® MagicTouch™) with a closed end
Description: This is a device used to help apply scleral lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three fingers (Patient's Hand)
Description: This is a device used to help apply scleral lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O-ring (Hardware Store Product)
Description: This is a device used to help apply scleral lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)
Description: This is a device used to help apply scleral lenses.
Study: NCT05042635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab+Jueyin Granules
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab+Jueyin placebo Granules
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Study: NCT05602090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 IU of recombinant GH (Somatotropin )
Description: 4 IU of recombinant GH
Study: NCT04953897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study: NCT06156592

Intervention type: PROCEDURE
Intervention: Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia
Description: Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.

Intervention type: PROCEDURE
Intervention: Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia
Description: Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
Study: NCT06129019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki application will be done
Study: NCT04662931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
Study: NCT05799105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 milligrams
Description: Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 milligrams
Description: Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
Study: NCT06545331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB010
Description: IV administration of XB010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB010
Description: IV administration of XB010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB010
Description: IV administration of XB010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration of Pembrolizumab
Study: NCT05972629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444836
Description: Infusion pump, intravenous infusion (IV)
Study: NCT05239455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveos® Automated Blood Processing System
Description: This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
Study: NCT05780983

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education and coaching on developing healthy nighttime sleep and daytime activity behaviors
Description: The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
Study: NCT05683691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanquish System
Description: Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
Study: NCT06643663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Micro-Surgery
Description: Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic Micro-Surgery
Description: Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
Study: NCT06643299

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Agent
Description: BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
Study: NCT06332807

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: adeno-associated viral vector with human phenylalanine hydroxylase gene
Study: NCT06067633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple-Masked
Description: Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Procedures
Description: Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
Study: NCT06405399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention. observation guide
Description: An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).